Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.
Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG; OLYMPIA 1 Investigators. Ständer S, et al. Among authors: tsianakas a. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4796. Online ahead of print. JAMA Dermatol. 2024. PMID: 39602139
Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study.
Renkhold L, Pereira MP, Loser K, Metze D, Baeumer D, Melzer N, Reinhardt M, Tsianakas A, Luger T, Mess C, Becker R, Hambüchen C, Agelopoulos K, Ständer S. Renkhold L, et al. Among authors: tsianakas a. Acta Derm Venereol. 2024 Nov 20;104:adv40737. doi: 10.2340/actadv.v104.40737. Acta Derm Venereol. 2024. PMID: 39565228 Free PMC article. Clinical Trial.
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crépy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S; trial investigators. Bissonnette R, et al. Lancet. 2024 Aug 3;404(10451):461-473. doi: 10.1016/S0140-6736(24)01027-4. Epub 2024 Jul 18. Lancet. 2024. PMID: 39033766 Clinical Trial.
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations.
Gooderham MJ, de Bruin-Weller M, Weidinger S, Cork MJ, Eichenfield LF, Simpson EL, Tsianakas A, Kerkmann U, Feeney C, Romero W. Gooderham MJ, et al. Among authors: tsianakas a. Dermatol Ther (Heidelb). 2024 Aug;14(8):2285-2296. doi: 10.1007/s13555-024-01200-5. Epub 2024 Jul 2. Dermatol Ther (Heidelb). 2024. PMID: 38954384 Free PMC article.
[Rehabilitation for patients with chronic pruritus].
Voigt TP, Tsianakas A. Voigt TP, et al. Among authors: tsianakas a. Dermatologie (Heidelb). 2024 Aug;75(8):617-622. doi: 10.1007/s00105-024-05382-z. Epub 2024 Jun 27. Dermatologie (Heidelb). 2024. PMID: 38935293 Review. German.
Publisher Erratum zu: Januskinaseinhibitoren.
von Martial S, Tsianakas A. von Martial S, et al. Among authors: tsianakas a. Dermatologie (Heidelb). 2024 Dec;75(Suppl 3):69-70. doi: 10.1007/s00105-024-05307-w. Dermatologie (Heidelb). 2024. PMID: 38376533 German. No abstract available.
82 results